90%Confidence
0Views
FDASource
2026-03-07Date
Summary
Repeat contamination issues with Asteria Health's testosterone pellets suggest systemic manufacturing problems that could lead to business suspension. This pattern of recalls may prompt FDA to take more severe regulatory action against the company.
Actionable: Immediately divest from Asteria Health and similar compounding pharmacies with repeated quality issues.
AI Confidence: 90%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 200 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1200-43.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now